Keywords: Bristol-Myers Squibb, Reyataz, AIDS drug pricing, AHF, ADAP
Bristol-Myers Squibb relents on AIDS drug pricing following sustained AHF advocacy campaign
Article | 13 August 2010
Following ongoing advocacy campaigns spearheaded by the USA-based AIDS Healthcare Foundation (AHF) that targeted several of the largest AIDS drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
